However, given that cellular metabolism is a complex process involving the activity of numerous genes, we cannot exclude that SHMT2 may also target tumor immunity and tumor progression by affecting the methylation status of mRNAs other than MYC in an m6A-dependent manner. The gene discussed is SHMT2; the disease is neoplasm.